首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FAM19A4 |
| Uniprot No | Q96LR4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 36-140aa |
| 氨基酸序列 | SQHLR GHAGHHQIKQ GTCEVVAVHR CCNKNRIEER SQTVKCSCFP GQVAGTTRAQ PSCVEASIVI QKWWCHMNPC LEGEDCKVLP DYSGWSCSSG NKVKTTKVTR |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于FAM19A4重组蛋白的3篇代表性文献的简要总结(注：文献为虚拟示例，实际研究需通过学术数据库核实)：
1. **文献名称**：*FAM19A4 as a novel secreted chemokine-like protein involved in tumor suppression*
**作者**：Zhang L, et al.
**摘要**：本研究成功表达并纯化了人源FAM19A4重组蛋白，发现其通过激活SFRP1/Wnt信号通路抑制宫颈癌细胞侵袭和迁移，提示其作为肿瘤抑制因子的潜在治疗价值。
2. **文献名称**：*Epigenetic silencing of FAM19A4 in cervical cancer and its functional rescue by recombinant protein treatment*
**作者**：Wang Y, et al.
**摘要**：通过体外实验证实，FAM19A4启动子甲基化导致其在宫颈癌中表达缺失。补充重组FAM19A4蛋白可显著诱导癌细胞凋亡并增强顺铂化疗敏感性，为表观遗传治疗提供依据。
3. **文献名称**：*Structural characterization and immunomodulatory activity of FAM19A4 recombinant protein*
**作者**：Kim JH, et al.
**摘要**：解析了FAM19A4重组蛋白的晶体结构，发现其通过TLR4/NF-κB通路调控巨噬细胞极化，在炎症性疾病模型中表现出抗炎作用，提示其免疫调节应用潜力。
**提示**：实际研究中，FAM19A4相关论文多集中于表观遗传学标志物(如宫颈癌甲基化筛查)，重组蛋白的功能研究相对较少。建议通过PubMed检索「FAM19A4 recombinant protein」或「FAM19A4 functional study」获取最新进展。
**Background of FAM19A4 Recombinant Protein**
FAM19A4 (Family with Sequence Similarity 19 Member A4), also known as TAFA-4. belongs to a family of secreted proteins characterized by conserved cysteine-rich domains. It is part of the larger TAFA family, which shares structural homology with chemokines but exhibits distinct functional roles. FAM19A4 is encoded by the *FAM19A4* gene and is expressed in various tissues, with notable presence in the nervous and immune systems. While its exact physiological function remains under investigation, studies suggest involvement in cell signaling, immune regulation, and neural development.
Emerging research highlights FAM19A4's association with disease pathways, particularly in cancer. Epigenetic silencing of *FAM19A4* via promoter hypermethylation has been identified as a biomarker for cervical cancer and precancerous lesions, especially in human papillomavirus (HPV)-negative cases. This methylation-driven inactivation is linked to tumor progression, making FAM19A4 a promising diagnostic and prognostic target.
Recombinant FAM19A4 protein is engineered using expression systems (e.g., *E. coli* or mammalian cells) to produce purified, biologically active forms for research and clinical applications. It enables studies on ligand-receptor interactions, signaling mechanisms, and its role in pathologies. In diagnostics, FAM19A4-based assays are being explored for non-invasive cancer screening. Additionally, recombinant protein tools aid in developing therapeutic strategies, such as antibody production or methylation analysis.
Despite progress, FAM19A4's full mechanistic profile and therapeutic potential require further exploration. Current efforts focus on elucidating its dual roles in homeostasis and disease, leveraging recombinant protein technology to bridge molecular insights with clinical translation.
×
